PHARMACY

Survey: Americans prefer pharmacy over physician when it comes to vaccines

BY Michael Johnsen

IRVINE, Calif. — The majority of Americans prefer visiting their local pharmacy to get their inoculations, as opposed to visiting the doctor's office, according to  the PrescribeWellness 2017 Vaccination and Preventive Care Survey.

Of the 62% of survey respondents who chose pharmacy over practitioner, most of the reasons hinged upon convenience.

As many as 26% stated their pharmacy is a “one-stop shop” for many health and wellness needs. Another 24% reported their local pharmacy is easier to get to than the doctor’s office while 21% suggested  their local pharmacy is more convenient than visiting a doctor’s office when they have the kids with them.

Specifically regarding the shingles vaccine, as many as 89% think it is important to get immunized, the survey found.

The reasons are varied, acording to survey respondents. As many as 73% think the shingles vaccine is important because shingles is painful, and 56% gravitate toward the inoculation because shingles takes a long time to heal. Approximately 60% of consumers are concerned about shingles because the virus can lie dormant for decades and 48% because it often affects the elderly, who are often less capable of caring for themselves.

As many as 40% of Americans have been directly affected by the shingles epidemic in some way, the survey found, with 22% reporting a member of their family has had shingles; 14% reporting their spouse has suffered from shingles; and 12% having friends who have been impacted.

The survey, which was conducted by Propeller Insights on behalf of PrescribeWellness, interiewed 1,000 American adults over 35 and gauged Americans’ feelings about vaccination and neighborhood pharmacies.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

What area is your company focused most on in 2019?
  • Add your answer
PHARMACY

Teva releases Minastrin generic

BY Brian Berk

JERUSALEM — Teva Pharmaceutical Industries on Monday launched an authorized Generic of Minastrin 24 Fe (norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets) 1 mg/20 mcg in the United States.

The authorized generic is an estrogen/progestin combined oral contraceptive indicated for use by women to prevent pregnancy.

Minastrin 24 Fe, manufactured by Allergan had annual sales of approximately $361 million in the U.S. according to IMS data as of December 2016.
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

What area is your company focused most on in 2019?
  • Add your answer
PHARMACY

OncBioMune acquires Mexican rights to norepinefrine from Teva

BY Brian Berk

BATON ROUGE, La. — OncBioMune Pharmaceuticals signed a non-binding term sheet with Teva Pharmaceuticals to acquire norepinefrine in Mexico. This agreement can also extend to other Latin American countries.

“Mexico is one of the top five emerging markets globally, principally with generics. Teva has a broad portfolio of generics that are overlapping in some strategic markets, which presented an opportunity for us to acquire another revenue-generating drug,” said Jonathan Head, Ph. D., Chief Executive Officer at OncBioMune. “We intend to remain aggressive in our acquisition strategy to grow our high specialty footprint in Mexico and across all of Central and South America to capitalize on the burgeoning markets. Pending the unexpected, I anticipate a definitive agreement and our acquisition of Norepinefrine during the second quarter of 2017, with commercialization efforts to commence shortly thereafter.”

The term sheet confirms mutual interest and sets forth guidelines for OncBioMune to acquire the sanitary registration and intellectual property rights of Norepinefrine currently owned by Teva. Norepinefrine is approved in Mexico as indicated for the treatment of low blood pressure and heart failure.

Baton Rouge-based OncBioMune is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary Vaccine Technology that is designed to stimulate the immune system to attack its own cancer while not hurting the patient.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

What area is your company focused most on in 2019?
  • Add your answer